The UK offices in London and Stirling now house nearly 130 Medpace employees as the company has increased its expansion efforts in Europe over the past few years.
The European activities have included adding additional clinical research professionals and expanding facilities in the UK, Poland, Russia, France, Germany and other expected expansions this year and next year in Leuven, Belgium, Prague and Madrid.
“We have been adding and enlarging our office spaces globally, however Europe continues to be a growth market for us – enabling us to better support a number of large global studies on behalf of our sponsors,” spokeswoman Mary Kuramoto told us. “Our key therapeutic areas are endocrinology, cardiovascular, oncology, and infectious disease….Medpace now has 12 offices in the EU and a Central Lab in Belgium.”
Ohio-based Medpace established its first European office in the Czech Republic in 2005, and then boosted its device offerings in the region with the acquisition of Meditech in 2012. Last year, UK-based private equity firm Cinven acquired Medpace for $915m, saying the company is particularly attractive given its focus on small- and mid-sized biotech, pharma and med device clients. The company also expanded into Asia last year by opening a new central lab in Singapore.
Medpace employees in Europe now account for over one third of its 2000 staffers. The company says it will continue to grow and offer services for studies in oncology, cardio metabolic, infectious disease, CNS, and other therapeutic areas.